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The historic discovery that the catecholamine neurotransmitters of the sympathetic nervous 
system, norepinephrine and epinephrine, are inactivated through their reuptake by presy-
naptic nerve terminals provided new insights into neurotransmitter action and paved the 
way for the development of modern antidepressant drugs.In 1970, the pioneering neuroscien-
tist Julius Axelrod shared the Nobel 
Prize in Physiology or Medicine with 
Sir Bernard Katz and Ulf von Euler 
“for their discoveries concerning the 
humoral transmitters in the nerve 
terminals and the mechanism for 
their storage, release and inactiva-
tion.” Axelrod’s third of the prize was 
awarded for his studies establishing 
that norepinephrine—the neurotrans-
mitter of sympathetic nerves and of 
many neurons in the brain—has its 
actions terminated through reuptake 
by the nerve endings that released it 
into the synapse (the space between 
the nerve ending and adjacent neu-
rons). Inactivation of a neurotransmit-
ter through its reuptake turned out to 
be the major mode of inactivation for 
other biogenic amines such as sero-
tonin and for amino acid neurotrans-
mitters, which together are the prin-
cipal neurotransmitters in the brain. 
The three 1961 papers that describe 
Axelrod’s discovery reflect a seminal 
event in understanding how neuro-
transmitters work and set the stage 
for the development of antidepres-
sants such as Prozac (which blocks 
the reuptake of serotonin).
The concept of chemical neuro-
transmission began at the turn of the 
twentieth century with the discovery of 
the catecholamine epinephrine (also 
called adrenalin), the hormone of the 
adrenal medulla responsible for the 
fight or flight response (Dale, 1960). 
In 1899, Lewandowsky first reported 
that the effects of stimulating sympa-
thetic nerves resembled influences 
produced by injecting animals with 
extracts of the adrenal gland. Soon 
thereafter John Jacob Abel, who 
founded the Pharma-
cology Department 
at the Johns Hop-
kins Medical School, 
isolated the active 
 principle of the adrenal 
medulla and named 
it epinephrine. T.R. 
Elliott in Cambridge, 
England showed that 
the effects of epinephrine adminis-
tration closely resembled those from 
stimulating sympathetic nerves. On 
May 21, 1904, at a meeting of the 
Physiological Society, Elliott pro-
posed “a mechanism developed out 
of the muscle cell, in response to its 
union with the synapsing sympa-
thetic fibre, the function of which is 
to receive and transform the nervous 
impulse. Adrenalin might then be the 
chemical stimulant liberated on each 
occasion when the impulse arrives at 
the periphery.” Elliott’s proposal was 
extraordinarily prescient. A century 
ago most students of the nervous sys-
tem assumed that electrical activity of 
a nerve simply “jumped the gap” to the 
adjacent nerve or organ. To conceptu-
alize chemical neurotransmission and 
to propose a specific chemical trans-
mitter that was almost exactly correct 
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colleagues were skeptical, as epine-
phrine did not perfectly reproduce the 
effects of sympathetic nerve stimula-
tion. In 1946, Ulf von Euler isolated the 
related chemical norepinephrine from 
sympathetic nerves and established it 
as the principal neurotransmitter of the 
sympathetic nervous system (epine-
phrine and norepinephrine differ by a 
single N-methyl group and exert very 
similar effects).
A more glamorous demonstra-
tion of chemical neurotransmission 
is credited to Otto von Loewi for his 
1921 experiment in which he stimu-
lated the vagus nerve that innervates 
heart muscle to slow the rate of the 
heart beat and then applied the fluid 
bathing the heart to an independ-
ent unstimulated heart whose rate 
in turn slowed. Pinning down the 
identity of the neurotransmitter for 
the vagus nerve (acetylcholine) was 
less of a challenge than identify-
ing norepinephrine as the principal 
neurotransmitter of the sympathetic 
nervous system because acetylcho-
line had already been characterized. 
Loewi together with Sir Henry Dale 
showed that acetylcholine’s actions 
closely corresponded to the results 
obtained when the vagus nerve was 
stimulated directly, resulting in their 
award of the 1936 Nobel Prize for 
Physiology or Medicine.
Inactivation of acetylcholine in 
the synapse was quickly shown to 
be due to the well-characterized 
enzyme acetylcholinesterase, and 
blocking the activity of acetylcho-
linesterase was shown to potentiate 
neurotransmission by acetylcholine. 25, April 7, 2006 ©2006 Elsevier Inc. 13
Figure 1. Norepinephrine Inactivation
Norepinephrine is the key neurotransmitter 
in the sympathetic nervous system. In a trio 
of 1961 papers, Julius Axelrod showed that 
norepinephrine is inactivated through its re-
uptake into sympathetic nerve terminals. 
He subsequently showed that blockade of 
reuptake by drugs such as cocaine or the 
antidepressant imipramine potentiated nore-
pinephrine activity in the sympathetic nervous 
system. Figure adapted from Axelrod’s Nobel 
oration (Axelrod, 1971).As acetylcholine was the first neu-
rotransmitter to be identified and 
characterized, it became axiomatic 
that for a chemical to be designated 
a neurotransmitter there must exist a 
specific enzyme for its inactivation. 
Norepinephrine in the brain and the 
sympathetic nervous system was 
found to be degraded by the enzyme 
monoamine oxidase and, by the mid-
1950s, monoamine oxidase inhibi-
tors had been developed as the first 
antidepressant drugs. But none of 
these drugs potentiated neurotrans-
mission in the sympathetic nervous 
system, and monoamine oxidase did 
not seem to account for all norepine-
phrine degradation. Enter Axelrod in 
1957 with his first major discovery: 
the identification of the enzyme cat-
echol-O-methyltransferase (COMT), 
which adds a methyl group to the 
meta position of norepinephrine or 
of any other catechol structure (Axel-
rod, 1957). Surprisingly, inhibitors of 
COMT also failed to potentiate sym-
pathetic neurotransmission. Thus, 
neither of the two enzymes that were 
known to degrade norepinephrine 
could explain its inactivation in the 
sympathetic nervous system.
How did Axelrod discover the 
reuptake mode of synaptic inac-
tivation for norepinephrine? Sey-
mour Kety, Director of the National 
Institute of Mental Health’s Labora-
tory of Clinical Science where Axel-
rod worked, had been tantalized 
by reports that abnormal oxidation 
products of epinephrine, such as 
adrenochrome, were uniquely con-
centrated in the urine of patients 
with schizophrenia. He sought to 14 Cell 125, April 7, 2006 ©2006 Elsevier compare the metabolism of cat-
echolamines between patients 
with schizophrenia and healthy 
control subjects. At considerable 
expense, Kety obtained from the 
New England Nuclear Corporation 
(now Perkin-Elmer) radiolabeled 
versions of norepinephrine and 
epinephrine, but he was unable 
to find any difference in catecho-
lamine metabolism between the 
two groups. Fortunately, there was 
sufficient [3H]-norepinephrine and 
[3H]-epinephrine left over for Axel-
rod to begin his series of ground-
breaking experiments. When he 
injected either [3H]-norepinephrine 
or [3H]-epinephrine into cats and 
rodents, the radiolabel persisted 
unchanged for several hours in 
organs rich in sympathetic nerves 
such as the heart, spleen, and sali-
vary gland. In a critical experiment 
proposed by Georg Hertting, a vis-
iting scientist, Axelrod and Hert-
ting directly tested the possibility 
that norepinephrine is taken up by 
sympathetic nerves (Hertting et al., 
1961a; Hertting and Axelrod, 1961). 
They removed the superior cervical 
ganglia of cats unilaterally lead-
ing to degeneration of the sympa-
thetic nerves to the salivary gland 
and eye muscles and showed that 
[3H]-norepinephrine accumulation 
was abolished in the denervated 
side. They then demonstrated that 
stimulation of the sympathetic 
nerves on the other side released 
the radiolabel into the endogenous 
norepinephrine pool. To my mind 
the clincher experiments estab-
lishing that reuptake inactivates Inc.norepinephrine came from Axel-
rod’s drug studies (see Figure 1). 
Cocaine was known to potentiate 
sympathetic neurotransmission, 
and Axelrod showed that admin-
istering cocaine before injecting 
[3H]-norepinephrine vastly reduced 
its uptake into the heart, whereas 
giving the drug after administering 
[3H]-norepinephrine had no effect 
(Hertting et al., 1961b). By contrast, 
tyramine, which releases norepine-
phrine from presynaptic nerve ter-
minals, reduced the concentration 
of the radiolabel in the heart to the 
same extent whether given before 
or after [3H]-norepinephrine.
In the same series of studies, 
Axelrod showed that the first major 
tricyclic antidepressant, imipramine, 
blocked [3H]-norepinephrine uptake 
(Axelrod et al., 1961). In these experi-
ments, it was not possible to examine 
the brain directly as the blood-brain 
barrier precluded entry of the radi-
olabeled catecholamine into brain 
tissue. Subsequently, Axelrod and 
Jacques Glowinski used intraven-
tricular injections of [3H]-norepine-
phrine to show that clinically effective 
(but not ineffective) antidepressants 
blocked norepinephrine accumula-
tion into brain tissue (Glowinski and 
Axelrod, 1964). Within a few years, 
it was established that serotonin is 
also inactivated by a reuptake proc-
ess similar to that for the catecho-
lamines. There followed decades 
of debate as to whether the relief 
of the clinical symptoms of depres-
sion stemmed from inhibition of the 
uptake of norepinephrine or of serot-
onin. With the development of drugs 
selective for inhibition of the uptake 
of one or the other neurotransmitter, 
we now know that both neurotrans-
mitters are important in depression.
All of Axelrod’s key experiments 
delineating the inactivation of nore-
pinephrine through its reuptake were 
done in a small laboratory at the 
National Institutes of Health with two 
or three colleagues. They were com-
pleted within the span of 1 to 2 years, 
with three key papers appearing in 
Science and Nature in 1961. At the 
same time that he was carrying out 
these landmark studies, Axelrod also 
was busy identifying the enzymes 
necessary for production of mela-
tonin, leading soon thereafter to his 
demonstration of its role as a major 
hormone of the pineal gland.
Often overlooked are the tools that 
make great scientific discoveries pos-
sible. It should be remembered that 
radiolabeled chemicals from com-
mercial sources only became readily 
available to biomedical researchers 
in the late 1950s. Axelrod’s break-
throughs would not have been pos-
sible without these substances. 
Besides the importance of [3H]-cat-
echolamines, a radiolabeled version 
of S-adenosylmethionine enabled 
Axelrod to discover several major 
methylating enzymes that are impor-tant in neurotransmitter metabolism. 
Besides COMT and the melatonin-
forming enzyme (which methylates 
N-acetylserotonin), he discovered 
the histamine-methylating enzyme as 
well as phenylethanolamine-N-meth-
yltransferase (PNMT), the enzyme 
that methylates norepinephrine to 
form epinephrine.
In the late 1960s and early 1970s, 
amino acid neurotransmitters such 
as γ-aminobutyric acid (GABA) and 
glutamate were established, quanti-
tatively speaking, as the major neu-
rotransmitters in the brain. GABA is 
the principal inhibitory neurotrans-
mitter of the brain and glutamate is 
the major excitatory neurotransmit-
ter; glycine serves as an inhibitory 
neurotransmitter in the spinal cord/
lower brain stem. All of these amino 
acid neurotransmitters owe their 
synaptic inactivation primarily to 
reuptake by the presynaptic nerve 
terminals. The transporter proteins 
that are responsible for reuptake 
of the biogenic amines and amino 
acid neurotransmitters are now well 
characterized.
Although Axelrod’s Nobel prize 
was awarded for elucidating the 
inactivation of neurotransmitters by 
reuptake, this was only a small part 
of his many contributions to science. Cell 12He identified what is now known as 
the cytochrome p450 family of drug-
metabolizing enzymes and discov-
ered melatonin as the hormone of 
the pineal gland, to cite but a few 
of his other innovations. Having 
begun his scientific life as a labora-
tory technician, finally earning a PhD 
when he was 43 years old, Axelrod 
worked directly at the lab bench well 
past retirement age and still visited 
his lab at the NIH into his nineties. 
He remained scientifically active 
until his sudden death in December 
2004 at age 92.
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